entospletinib   Click here for help

GtoPdb Ligand ID: 7889

Synonyms: GS-9973
PDB Ligand
Compound class: Synthetic organic
Comment: Entospletinib is a highly selective and orally available Syk inhibitor. Its discovery (research code GS-9973) is described in [1] where it is compound 68.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 83.37
Molecular weight 411.18
XLogP 4.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O1CCN(CC1)c1ccc(cc1)Nc1nc(cn2c1ncc2)c1ccc2c(c1)[nH]nc2
Isomeric SMILES O1CCN(CC1)c1ccc(cc1)Nc1nc(cn2c1ncc2)c1ccc2c(c1)[nH]nc2
InChI InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
InChI Key XSMSNFMDVXXHGJ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Entospletinib is being evaluated in clinical trials for oncology indications. Two Phase 2 clinical trials are ongoing. The first is in combination with idelalisib (NCT01796470), the second is as a mono-therapy (NCT01799889), both are in subjects with relapsed or refractory hematologic malignancies.